DJIA 17,083.80 -2.83 -0.02%
NASDAQ 4,472.11 -1.59 -0.04%
S&P 500 1,987.98 0.97 0.05%
market minute promo

Nektar Therapeutics (NASDAQ: NKTR)



company name or ticker

Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourou

Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium

Pipeline Progress at Nektar - Analyst Blog

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential

Nektar Therapeutics' CEO Presents at 32nd Annual JPMorgan Healthcare Conference (Transcript)

Cadence Pharmaceuticals Inc. (CADX) Soars: Stock Adds 13.0% in Session - Tale of the Tape

Time to Buy Nektar Therapeutics (NKTR) After Recent Moving Average Crossover? - Tale of the Tape

Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Pat

Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape

Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape

MannKind's Pit Stop on the Road to Approval

MannKind's inhaled insulin Afrezza will face an advisory committee meeting in April.

Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire

See More Articles...